ClinicalTrials.gg
CompletedNCT03284931Updated Nov 29, 2023

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

A Phase 1 interventional study of SAGE-217 high dose and Placebo in Healthy, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2017, 8 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This study will assess the pharmacodynamic effects of SAGE-217 in approximately 42 healthy adult subjects using an insomnia model.

Read the detailed description

Subjects are expected to complete Treatment Periods 1, 2 and 3, followed by an optional open-label administration of SAGE-217 for pharmacokinetic purposes (Treatment Period 4).

This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is willing and able to participate in the study, including all assessments, planned inpatient stays and all follow-up visits
  • Subject is a healthy, ambulatory volunteer
  • Subject meets sleep Qualification criteria

Exclusion criteria

Exclusion Criteria:

  • Subject has a medical history of suicidal behavior, epilepsy, eating disorders, sleep disorders, or circadian rhythm disorders
  • Subject has worked a night shift or flown >1 time zone within 30 days prior to Screening
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    SAGE-217 high dose

    SAGE-217

    Drug: SAGE-217 high dose

  • Experimental
    SAGE-217 low dose

    SAGE-217

    Drug: SAGE-217 low dose

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Sleep efficiency, as determined by polysomnography (PSG)

    Time frame: 16 days

Secondary outcomes

  1. Safety and tolerability, as assessed by adverse events

    Time frame: 36 days

  2. Safety and tolerability, as assessed by vital signs

    Time frame: 29 days

  3. Safety and tolerability, as assessed by clinical laboratory data

    Time frame: 29 days

  4. Safety and tolerability, as assessed by ECG

    Time frame: 29 days

  5. Safety and tolerability, as assessed by Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: 29 days

07

Study locations

1 site
  • Sage Investigational Site
    New York, New York 10019, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Dec 2017, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2017
First posted
Sep 15, 2017
StartActual
Sep 14, 2017
Primary completionActual
Dec 4, 2017
CompletionActual
Dec 18, 2017
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03284931
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Sep 15, 2017
Start date
Sep 14, 2017
Primary completion
Dec 4, 2017
Completion
Dec 18, 2017
Last update
Nov 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zuranolone

Start the discussion